Acute dystonic dyskinesias in a patient used fluvoxamine. Case report
Objective: To represent a case of acute dystonic dyskinesias after fluvoxamine use by the patient with obsessive thoughts and movements. Background: In psychiatric clinical practice,…Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…Genetic Variants and Levodopa Response in Parkinson’s Disease: Insights from MAO-B and DAT1 Polymorphisms
Objective: This study aimed to find the association of genetic variations between Parkinson’s disease (PD) patients with and without levodopa-induced dyskinesia (LID). we intended to…Validation of the Kazakh Version of the Movement Disorder Society-Unified Dyskinesia Rating Scale.
Objective: This study aimed to validate the Kazakh version of the Movement Disorder Society-Unified Dyskinesia Rating Scale Background: The Unified Dyskinesia Rating Scale (UDysRS) has…Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology
Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…Triple threat: A rare case of a patient with 3 co-existent autoimmune antibodies causing autonomic and movement disorder
Objective: We describe a unique case of a patient with a constellation of movement and autonomic abnormalities. Serum paraneoplastic/autoimmune testing was positive for 3 separate…MOVE-PD: Mapping the Correlation of Sedentary behavior with Motor Symptoms in Parkinson’s Disease
Objective: Mapping the correlation between sedentary behavior (SB) and Parkinsons (PD) specific motor symptoms, measured on objective data from wearables. Background: People with Parkinson's (Pwp)…Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in the treatment of patients with advanced Parkinson’s Disease (APD). Background: The continuous enteral infusion…Autoimmune Movement Disorders: An Illustrative Case Series of 8 Patients.
Objective: The aim of this study is to describe the variability of presentations, etiology, management, follow up and outcome of autoimmune encephalitis, a potentially reversible…Uncovering Patient Perspectives on Parkinson’s Disease to Inform Individualized Care
Objective: To gather patient insights on the burden of Parkinson’s disease (PD), understand the level of patient involvement in treatment decision-making, and determine overall satisfaction…
- 1
- 2
- 3
- …
- 40
- Next Page »